UNSPSC 51172145: Pimetremide

This classification denotes an antispasmotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3VY58MWL7J. European Medicines Agency schedules Pimetremide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09842MIG. Pimetremide generally arises in the molecular formula C16H18N2O2.

UNSPSC 51172145 Pimetremide (Commodity) covers pharmaceutical products, though recent state and local procurement under this code spans a broader range of pharmaceutical and drug-testing services than the specific compound name suggests. State and local buyers are acquiring specimen collection and drug testing services, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals with OTC products through cooperative purchasing. Issuing bodies include county community supervision and corrections departments (Collin County, Texas), state health and human services commissions (Texas HHS Commission), and state-administered cooperative purchasing alliances serving multiple jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The mix reflects county operational needs, state health program administration, and multi-state collective procurement vehicles.

Activity clusters in Texas and the upper Midwest, with significant recent solicitation in both states. Collin County Community Supervision and Corrections Department posted RFP 2026-327 for Offender Specimen Collection and Drug Testing Services on July 9, 2026, with proposals due July 23, 2026, seeking to staff two collection sites in Plano and McKinney, operate randomized testing via Interactive Voice Response, perform immunoassay screening with LC/MS/MS or GC/MS confirmation, and provide oral fluid and hair testing under SAMHSA, TX DPS, or CAP certification; estimated contract value is $600,000 over two years with three optional one-year renewals. Texas HHS Commission issued RFI HHS0017013 on March 27, 2026, closing April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. Minnesota Department of Administration's Office of State Procurement, administering MMCAP, posted RFP S1070000015802 on January 20, 2026, with proposals due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers to participating state and local government facilities in Minnesota and Oregon.